Yin Liu1, Puspa R Pandey2,3, Sambad Sharma1, Fei Xing1, Kerui Wu1, Amar Chittiboyina4, Shih-Ying Wu1, Abhishek Tyagi1, Kounosuke Watabe5. 1. Department of Cancer Biology, Wake Forest School of Medicine, Winston Salem, NC, 27151, USA. 2. Department of Medical Microbiology, Immunology & Cell Biology, Southern Illinois University School of Medicine, Springfield, IL, USA. 3. Lonza Walkersville, Inc, Walkersville, MD, USA. 4. School of Pharmacy, University of Mississippi, Oxford, MS, USA. 5. Department of Cancer Biology, Wake Forest School of Medicine, Winston Salem, NC, 27151, USA. kwatabe@wakehealth.edu.
Abstract
PURPOSE: Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer which could progress to or recur as invasive breast cancer. The underlying molecular mechanism of DCIS progression is yet poorly understood, and appropriate biomarkers to distinguish benign form of DCIS from potentially invasive tumor are urgently needed. METHODS: To identify the key regulators of DCIS progression, we performed gene-expression analysis of syngeneic breast cancer cell lines MCF10A, DCIS.com, and MCF10CA and cross-referenced the targets with patient cohort data. RESULTS: We identified ID2 as a critical gene for DCIS initiation and found that ID2 promoted DCIS formation by enhancing cancer stemness of pre-malignant cells. ID2 also plays a pivotal role in survival of the aggressive cancer cells. In addition, we identified INHBA and GJB2 as key regulators for the transition of benign DCIS to aggressive phenotype. These two genes regulate migration, colonization, and stemness of invasive cancer cells. Upregulation of ID2 and GJB2 predicts poor prognosis after breast-conserving surgery. Finally, we found a natural compound Helichrysetin as ID2 inhibitor which suppresses DCIS formation in vitro and in vivo. CONCLUSION: Our results indicate that ID2 is a key driver of DCIS formation and therefore is considered to be a potential target for prevention of DCIS, while INHBA and GJB2 play vital roles in progression of DCIS to IDC and they may serve as potential prognosis markers.
PURPOSE:Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer which could progress to or recur as invasive breast cancer. The underlying molecular mechanism of DCIS progression is yet poorly understood, and appropriate biomarkers to distinguish benign form of DCIS from potentially invasive tumor are urgently needed. METHODS: To identify the key regulators of DCIS progression, we performed gene-expression analysis of syngeneic breast cancer cell lines MCF10A, DCIS.com, and MCF10CA and cross-referenced the targets with patient cohort data. RESULTS: We identified ID2 as a critical gene for DCIS initiation and found that ID2 promoted DCIS formation by enhancing cancer stemness of pre-malignant cells. ID2 also plays a pivotal role in survival of the aggressive cancer cells. In addition, we identified INHBA and GJB2 as key regulators for the transition of benign DCIS to aggressive phenotype. These two genes regulate migration, colonization, and stemness of invasive cancer cells. Upregulation of ID2 and GJB2 predicts poor prognosis after breast-conserving surgery. Finally, we found a natural compound Helichrysetin as ID2 inhibitor which suppresses DCIS formation in vitro and in vivo. CONCLUSION: Our results indicate that ID2 is a key driver of DCIS formation and therefore is considered to be a potential target for prevention of DCIS, while INHBA and GJB2 play vital roles in progression of DCIS to IDC and they may serve as potential prognosis markers.
Entities:
Keywords:
Breast cancer; Cancer prevention; DCIS; IDC
Authors: Anna Lasorella; Renata Boldrini; Carlo Dominici; Alberto Donfrancesco; Yoshifumi Yokota; Alessandro Inserra; Antonio Iavarone Journal: Cancer Res Date: 2002-01-01 Impact factor: 12.701
Authors: S J Santner; P J Dawson; L Tait; H D Soule; J Eliason; A N Mohamed; S R Wolman; G H Heppner; F R Miller Journal: Breast Cancer Res Treat Date: 2001-01 Impact factor: 4.872
Authors: H G Burger; E C Dudley; J L Hopper; N Groome; J R Guthrie; A Green; L Dennerstein Journal: J Clin Endocrinol Metab Date: 1999-11 Impact factor: 5.958
Authors: Max A K Rätze; Thijs Koorman; Thijmen Sijnesael; Blessing Bassey-Archibong; Robert van de Ven; Lotte Enserink; Daan Visser; Sridevi Jaksani; Ignacio Viciano; Elvira R M Bakker; François Richard; Andrew Tutt; Lynda O'Leary; Amanda Fitzpatrick; Pere Roca-Cusachs; Paul J van Diest; Christine Desmedt; Juliet M Daniel; Clare M Isacke; Patrick W B Derksen Journal: Oncogene Date: 2022-04-18 Impact factor: 8.756